Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT05970718
- Locations
- 🇳🇿
New Zealand Clinical Research, Christchurch, New Zealand
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05955508
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇪🇸Clinica Universidad de Navarra - Madrid, Madrid, Spain
🇪🇸University Hospital Doctor Peset, Valencia, Spain
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05923424
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg Campus, Leuven, Belgium
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
- Conditions
- Bullous Pemphigoid
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT05906706
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
- Conditions
- Eosinophilic Gastritis (EoG)Eosinophilic Duodenitis (EoD)Eosinophilic Gastrointestinal Disease (EGID)Eosinophilic Gastroenteritis
- Interventions
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT05831176
- Locations
- 🇺🇸
Om Research LLC, Lancaster, California, United States
🇺🇸Scripps Memorial Hospital La Jolla, La Jolla, California, United States
🇺🇸University of California - Los Angeles (UCLA), Los Angeles, California, United States
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT05828511
- Locations
- 🇫🇷
Centre Hospitalier Universitaire (CHU) Montpellier, Montpellier, France
🇫🇷Hopital Saint Louis, Paris, France
🇫🇷Hopital Pitié Salpetriere APHP, Paris, France
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 950
- Registration Number
- NCT05800015
- Locations
- 🇺🇸
Crosson Cancer Institute, Fullerton, California, United States
🇺🇸Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸Yuma Regional Medical Center, Yuma, Arizona, United States
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
- Conditions
- Suspected EndophthalmitisIntraocular Inflammation
- Interventions
- Other: Non Applicable
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 155413
- Registration Number
- NCT05791695
- Locations
- 🇺🇸
Regeneron Research Site, Tarrytown, New York, United States
A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
- Conditions
- Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
- Interventions
- Genetic: DB-OTO
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT05788536
- Locations
- 🇺🇸
University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Nemours Children s Clinic, Jacksonville, Florida, United States
🇺🇸Nemours Childrens Hospital, Orlando, Florida, United States
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 850
- Registration Number
- NCT05785767
- Locations
- 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸Desert Hematology Oncology Medical Group Incorporated, Rancho Mirage, California, United States